Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(ANTX) stock logo
ANTX
(ANTX)
$1.09
-10.7%
$0.00
$0.87
$3.07
$33.76M0.15367,715 shs83,337 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$8.90
-0.2%
$9.59
$8.06
$18.15
$118.99M1.6946,152 shs33,040 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$8.69
-9.3%
$9.10
$7.65
$45.42
$128.70M-0.2669,045 shs229,031 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$2.53
+1.2%
$2.63
$1.12
$3.13
$116.33M0.6816,843 shs179,134 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(ANTX) stock logo
ANTX
(ANTX)
0.00%+1.40%-8.40%-26.85%-48.34%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
0.00%-3.26%-9.28%-20.89%-45.30%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
0.00%-10.78%+3.92%-22.30%-78.80%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
0.00%+2.02%-4.17%+61.15%+94.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1.5092 of 5 stars
3.51.00.00.00.03.30.0
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
2.9564 of 5 stars
2.83.00.00.01.15.01.3
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(ANTX) stock logo
ANTX
(ANTX)
2.00
Hold$1.5037.61% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00338.20% Upside
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
1.50
Reduce$20.00130.15% Upside
Theratechnologies Inc. stock logo
THTX
Theratechnologies
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ANTX, GLSI, LYEL, and THTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2025
(ANTX) stock logo
ANTX
(ANTX)
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $2.00
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
4/16/2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.00
4/11/2025
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.19 per shareN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$60K2,144.98N/AN/A$26.21 per share0.33
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$88.67M1.31N/AN/A($0.55) per share-4.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/6/2025 (Estimated)
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$8.31M-$0.08N/A36.14N/A-4.18%N/A-0.37%7/9/2025 (Estimated)

Latest ANTX, GLSI, LYEL, and THTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/13/2025Q1 2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$3.80-$3.60+$0.20-$0.18N/A$0.01 million
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.91
1.91
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
7.49
7.49
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
1.08
0.88

Institutional Ownership

CompanyInstitutional Ownership
(ANTX) stock logo
ANTX
(ANTX)
90.47%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
66.05%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A

Insider Ownership

CompanyInsider Ownership
(ANTX) stock logo
ANTX
(ANTX)
20.79%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.67%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
22.30%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.46 millionNot Optionable
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
27014.81 million11.51 millionOptionable
Theratechnologies Inc. stock logo
THTX
Theratechnologies
14045.98 millionN/AOptionable

Recent News About These Companies

Theratechnologies to further evaluate potential sale of the company
Theratechnologies Provides Update on Sale Process
Theratechnologies Provides Update on Sale Process
Theratechnologies receives FDA approval of PAS for EGRIFTA SV sBLA

New MarketBeat Followers Over Time

Media Sentiment Over Time

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$8.90 -0.02 (-0.22%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$8.88 -0.03 (-0.28%)
As of 06/20/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$8.69 -0.89 (-9.29%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$9.10 +0.41 (+4.72%)
As of 06/20/2025 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Theratechnologies stock logo

Theratechnologies NASDAQ:THTX

$2.53 +0.03 (+1.20%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$2.57 +0.04 (+1.58%)
As of 06/20/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.